Last reviewed · How we verify
NCT05790785
Vascular Complications in Children From T1D Diagnosis
trial in Type 1 Diabetes in 150 participants. Currently enrolling.
30 September 2027
Quick facts
| Lead sponsor | University of British Columbia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 25 March 2024 |
| Primary completion | 30 September 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Canada |
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
- Cardiovascular Complications — all drugs for Cardiovascular Complications →
- Child — all drugs for Child →
- Adolescent — all drugs for Adolescent →
Sponsor
University of British Columbia
Who can join
Adults 8 to 18, any sex, with Type 1 Diabetes or Cardiovascular Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Understanding vascular complications in children from type 1 diabetes diagnosis: protocol for a prospective cohort study in Vancouver, Canada.
Wiedeman AM, Panagiotopoulos C, Devlin AM. · · 2025 · PMID 40940049 · DOI 10.1136/bmjopen-2024-093842
Verify or expand the search:
- PubMed search for NCT05790785
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other University of British Columbia trials
Trials by the same sponsor.
- NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
- NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
- NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
- NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
- NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05790785 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
- Last refreshed: 2 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05790785.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing